Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 5 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.

Antidepressants show potential for managing depression in schizophrenia

01 Oct 2017

Antidepressants may be effective for treating depression in patients with schizophrenia, according to a meta-analysis that underscores qualifying conclusions based on the small number of low- or moderate-quality studies.

Researchers performed a meta-analysis of 26 trials that included adult patients with schizophrenia or related psychosis who had a depressive episode. Based on the Cochrane risk bias tool, the quality of the studies was moderate to low.

Pooled data indicated that antidepressants (eg, selective serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants) had a favourable effect on the risk of depression compared with placebo, with a small risk difference –0.19 (95 percent CI, –0.27 to –0.11) and corresponding number needed to treat of 5 (4 to 9).

The effect size was larger in studies using tools specifically designed to assess depression in schizophrenia. On sensitivity analysis, however, standardized mean difference of all antidepressants, as well as any individual antidepressant class, showed no statistically significant improvement in depression score at endpoint.

In light of the methodological limitations of current published findings, researchers recommend that future large-scale trials should prioritize the appropriate measurement of depressive symptoms in schizophrenia, include reporting of adverse outcomes, and use an adequate method of randomization, allocation, concealment and specific depression inclusion criteria.   

Depression contributes to the extensive burden of schizophrenia, and its management is crucial to recovery. Improvement in depression status may result in better long-term functional outcomes, including medication adherence, service utilization, substance misuse, suicide attempts and quality of life. [Schizophr Res 2016;172:23–28]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 5 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.